Germany approves first trial of coronavirus vaccine candidate
BioNTech said it was developing four vaccine candidates under a program named BNT162 with its partner, pharma giant Pfizer.
An employee of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen, Germany(photo credit: REUTERS/ANDREAS GEBERT)ByREUTERS
